3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
7
Genitourinary
3
Sarcoma
2
Gastrointestinal
2
Breast
2
Thoracic
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
CNS
1
Conditions
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
59
Nivolumab
34
Cyclophosphamide
21
fludarabine
15
Paclitaxel
12
Ipilimumab
12
atezolizumab
11
Specimen Handling
11
Magnetic Resonance Spectroscopy
10
Carboplatin
10
Docetaxel
9
Cisplatin
9
Gemcitabine
8
Biopsy
8
durvalumab
7
aldesleukin
7
Radiosurgery
7
Interleukin-2
7
Bevacizumab
7
cemiplimab
6
Pemetrexed
6
fludarabine phosphate
5
avelumab
5
Radiotherapy
5
Drug Therapy
5
spartalizumab
4
epacadostat
4
enzalutamide
4
Taxes
4
Sirolimus
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Melanoma
×
bempegaldesleukin
×
Gastrointestinal
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts